-
Clinical and Translational Data from RVU120 and SEL24(MEN1703) programs to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 44th Annual San Antonio Breast Cancer Symposium (SABCS)
Read More
November 4, 2021 -
Filing a lawsuit against Mota-Engil Central Europe S.A. in connection with construction of the Research and Development Center
Read More
September 24, 2021 -
First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors
Read More
August 25, 2021 -
Resignation of the Member of the Management Board
Read More
August 25, 2021 -
Notification from Aviva Otwarty Fundusz Emerytalny Aviva Santander on exceeding the threshold of 5% of the total number of votes in the Company
Read More
August 18, 2021 -
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
August 13, 2021 -
Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
July 21, 2021 -
FDA lifts partial clinical hold on RVU120 (SEL120) Phase Ib study in acute myeloid leukemia and myelodysplastic syndrome
Read More
July 14, 2021 -
Notifications from persons discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
July 13, 2021 -
Information on the change in the shareholder structure due to execution of the Stock Grant Program in the Company – Art. 69 of the Act on Offerings
Read More
July 9, 2021 -
Correction of the current report No. 22/2021 of July 8, 2021
Read More
July 8, 2021 -
Conclusion of the share donation agreement between the Company and President of the Management Board and main shareholder of the Company in execution of a non-diluting incentive program in the Company
Read More
July 8, 2021 -
Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June, 29 2021
Read More
June 30, 2021 -
Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
June 30, 2021 -
Publication of clinical data for phase I RVU120 and phase I/II SEL24 (MEN1703)
Read More
June 11, 2021 -
Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
June 2, 2021 -
Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
Read More
May 28, 2021 -
Publication of abstract related to SEL24 (MEN1703) program at ASCO Annual Meeting 2021
Read More
May 20, 2021 -
Shareholders controlling at least 5% of the vote at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on May 17, 2021
Read More
May 17, 2021 -
Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
May 17, 2021
Report: Current Stock Reports
Title